Chen JM, Zhong YT, Tu C, Lan J. Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis. World J Clin Cases 2020; 8(16): 3458-3464 [PMID: 32913852 DOI: 10.12998/wjcc.v8.i16.3458]
Corresponding Author of This Article
Jun Lan, MD, Chief Physician, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, No. 1 Xianglong Road, Dongguan 523326, Guangdong Province, China. dglanjun@163.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 26, 2020; 8(16): 3458-3464 Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3458
Significance of serum fibroblast growth factor-23 and miR-208b in pathogenesis of atrial fibrillation and their relationship with prognosis
Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan
Jie-Min Chen, Yao-Tang Zhong, Chang Tu, Jun Lan, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, Dongguan 523326, Guangdong Province, China
Author contributions: Chen JM and Zhong YT designed this retrospective study; Chen JM wrote this paper; Tu C was responsible for sorting the data.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Dongguan Songshan Lake Central Hospital.
Informed consent statement: Informed consent was obtained from the patients.
Conflict-of-interest statement: Dr. Lan J reports a grant from Dongguan Social Science and Technology Development Project (No. 2015108101025) during the conduct of the study. Other authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jun Lan, MD, Chief Physician, Department of Cardiovascular Medicine, Dongguan Songshan Lake Central Hospital, Dongguan Institute of Cardiovascular Disease, No. 1 Xianglong Road, Dongguan 523326, Guangdong Province, China. dglanjun@163.com
Received: April 9, 2020 Peer-review started: April 9, 2020 First decision: April 29, 2020 Revised: May 12, 2020 Accepted: July 14, 2020 Article in press: July 14, 2020 Published online: August 26, 2020 Processing time: 137 Days and 23.8 Hours
ARTICLE HIGHLIGHTS
Research background
The incidence and prevalence of atrial fibrillation are increasing each year, and this condition is one of the most common clinical arrhythmias
Research motivation
The identification of useful serological markers can provide guidance for the primary prevention of atrial fibrillation and for monitoring and evaluating treatment efficacy and prognosis
Research objectives
To investigate the levels and significance of serum fibroblast growth factor (FGF)-23 and miR-208b in atrial fibrillation and their relevance to patient prognosis
Research methods
A total of 240 patients with atrial fibrillation treated at our hospital from May 2018 to October 2019 were included.
Research results
The serum levels of FGF-23 and miR-208b in the observation group were significantly higher than the corresponding values in the control group. In the observation group, the serum levels of FGF-23 and miR-208b in patients with persistent atrial fibrillation were significantly higher than those in patients with paroxysmal atrial fibrillation. The left atrial dimension (LAD) of patients with persistent atrial fibrillation was significantly higher than that of patients with paroxysmal atrial fibrillation. The serum levels of FGF-23 and miR-208b were positively correlated with the LAD. In the observation group, the serum levels of FGF-23 and miR-208b in patients with a major cardiovascular event (MACE) were significantly higher than the corresponding values in patients without a MACE.
Research conclusions
Serum FGF-23 and miR-208b levels are elevated in patients with atrial fibrillation and correlate with disease type, cardiac parameters, and prognosis.
Research perspectives
Our findings may suggest a new method for evaluating the condition of atrial fibrillation.
